Safety and Tolerability Study for T-1101 (Tosylate) Capsules to Treat Advanced Refractory Solid Tumors
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
T-1101 (Tosylate) is a new small molecule chemical entity being developed as a potential
anti-cancer therapeutic by Taivex Therapeutics Corp. T-1101 (Tosylate) is a potent
anti-cancer agent in numerous human cancer cell lines. In addition, oral administration of
T-1101 (Tosylate) showed tumor growth inhibition in different mouse xenograft models of human
cancers. In this study, safety, tolerability and pharmacokinetic (PK) of T-1101 (Tosylate)
capsules will be evaluated and also the recommended dose and regimen(s) to initiate Phase 2
will be determined.